A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Completed · Phase 3 · NCT03104374
Conditions: Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $30,394
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 642
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo (drug), Upadacitinib (drug)
- Dates
- Started 2017-05-01; completion 2024-09-30
- Results posted
- Yes
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who had an inadequate response to Biological Disease Modifying Anti-Rheumatic Drug (bDMARDs). Period 2 evaluated the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who completed Period 1.
From ClinicalTrials.gov, last updated 2025-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $30,394 in research payments for this study in 2025 (5 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christine T. Thai, M.D. Rheumatology · Huntington Beach, CA
- Atul K. Singhal, M.D. FACR Rheumatology · Mesquite, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Southwest Rheumatology Research LLC $28,269
- Care Access Research LLC $2,125
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.